Clinical studies have suggested no beneficial effect of metoprolol, a β1-AR blocker, in Dox-treated lymphoma patients [15] but a beneficial effect of nebivolol, a β1-AR blocker associated to a β3-AR agonistic properties against anthracycline-induced cardiomyopathy in patients with breast cancer [55]. This evidence concerns the gene ADRB1 and lymphoma.